Vericiguat improves cardiac function and microcirculation of a male patient with Fabry disease: A case report

Ann Noninvasive Electrocardiol. 2024 May;29(3):e13115. doi: 10.1111/anec.13115.

Abstract

Fabry disease (FD) is a rare X chromosome-linked disorder and can be easily misdiagnosed. Here, we report the case of a 69-year-old male patient with FD who developed heart failure and showed extremely high pulmonary artery pressure. His initial symptom was recurrent atrial fibrillation. The left and right atrial inner diameters were large, and the ventricular wall was thick. Gene analysis which showed GLA c.215T>C p.Met72Thr mutation and single photon emission computed tomography indicated the diagnosis of FD with coronary microvascular dysfunction. The patient was prescribed anti-heart failure drugs, including vericiguat. Following the treatment, his heart function and microvascular perfusion significantly improved, which might be due to the beneficial effects of vericiguat.

Keywords: Fabry disease; Vericiguat; atrial fibrillation/atrial arrhythmias; electrophysiology; pharmacology.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Electrocardiography
  • Fabry Disease* / complications
  • Fabry Disease* / diagnosis
  • Fabry Disease* / drug therapy
  • Heterocyclic Compounds, 2-Ring*
  • Humans
  • Male
  • Microcirculation
  • Mutation
  • Pyrimidines*

Substances

  • vericiguat
  • Heterocyclic Compounds, 2-Ring
  • Pyrimidines